Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLGW) Gains from Investment Securities (2016 - 2017)

Bone Biologics (BBLGW) has disclosed Gains from Investment Securities for 2 consecutive years, with $412531.0 as the latest value for Q3 2017.

  • Quarterly Gains from Investment Securities fell 93.52% to $412531.0 in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $412531.0 through Sep 2017, down 93.52% year-over-year, with the annual reading at -$3967.0 for FY2025, 92.23% up from the prior year.
  • Gains from Investment Securities for Q3 2017 was $412531.0 at Bone Biologics, up from $80341.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $6.4 million in Q2 2016, with the low at -$502.0 in Q4 2016.